Veritas Pharma Inc. VRTHF Archives

FridayAug 30, 2019 11:44 am

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Committed to Developing Most Effective Proprietary Cannabis Strains and Products

The company recently completed clinical trials for its acute pain formulation, CTL-X, which is the most advanced product in the Veritas pipeline Veritas Pharma works in two directions to put together effective cannabis-based treatments for various medical conditions With the help of R&D partner Cannevert Therapeutics, Veritas is developing solutions for various additional issues like chronic pain and sleep disorders Pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is on a mission to develop the most effective proprietary cannabis strains and products for the treatment of various medical conditions. The company focuses on providing…

WednesdayFeb 28, 2018 10:26 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists…

FridayFeb 23, 2018 11:29 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Signs Agreement to Acquire Sechelt Organic Marijuana Corp.

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has signed an agreement with 906474 ALBERTA LTD (“the vender”), to purchase 100% ownership of Sechelt Organic Marijuana Corp (“SOM”). Under the agreement, Veritas Pharma will purchase all outstanding shares of SOM at a price of $800,000, subject to provisions of the closing agreement. The agreement requires the vender and SOM to give Veritas Pharma unlimited access to the operations, assets, properties, and records of SOM to help it familiarize with the operations, assets, records, properties and other matters on continuous…

WednesdayFeb 21, 2018 10:29 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Issues Corporate Update Detailing Q1 2018 Milestones

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of the University of British Columbia, its subsidiary’s progress toward the commencement of human trials in Puerto Rico studying lead cannabis strain CTL-X for pain management, its reception of a Health Canada dealer license through subsidiary Cannevert Therapeutics Ltd. (“CTL”) and CTL’s initiation of a cancer…

TuesdayFeb 20, 2018 10:23 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Preparing for Planned Q1 Takeover of Cannevert Therapeutics

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), alongside research arm Cannevert Therapeutics Ltd., this morning announced that it is in the process of obtaining a fairness opinion from Davidson & Company LLP of Vancouver, Canada, regarding Veritas’ planned acquisition of the remaining 20 percent of Cannevert in the first quarter of 2018. Per the update, a fairness opinion is defined as “any written communication containing a conclusion as to the fairness of a proposed transaction to security holders, from a financial point of view.” Davidson & Company is expected to perform this…

TuesdayJan 09, 2018 11:09 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Responds to Cole Memo Repeal

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis…

TuesdayJan 02, 2018 10:45 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung cancer. He is also an active clinical researcher committed to investigating new treatment strategies in airways disease. “Dr. O’Connor brings a great reputation of clinical excellence and scholarly research,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “He will advise us on…

FridayDec 29, 2017 10:44 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning's update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial…

ThursdayDec 28, 2017 11:16 am

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Subsidiary Receives Dealer License from Health Canada

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that Health Canada has issued its research and development subsidiary, Cannevert Therapeutics Ltd. (“CTL”), a dealer license allowing it to possess, analyze, sale, send, transport and deliver cannabis, hemp and related products. Per the release, reception of this license marks a “significant step” for CTL as it seeks to discover and develop new therapeutic cannabis strains while also providing commercial chemical and biological testing services for licensed producers under Health Canada guidelines. “We are excited that Cannevert scientists will now not only…

FridayDec 22, 2017 1:15 pm

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) to Leverage Unique Compound Synergies for Pain Moderation

Based on evidence that cannabinoids and opioids can work in synergy to moderate pain, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) and its research arm, Cannevert Therapeutics Ltd., intend to boost actions of opioid analgesics with a specific strain of cannabis. A recent article highlights the company’s approach in developing quality strains, stating, “Veritas Pharma employs a scientific approach to support medical cannabis claims and is intent on developing and commercializing the most effective strains of cannabis for medical use. The company is concerned that, with the rapid growth of the medical cannabis industry, product quality is inconsistent and…

Site Search

Company Search

Tag: Veritas Pharma Inc. VRTHF